Calidi Biotherapeutics, Inc. CLDI
are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic
medicines to distal sites of disease. Our proprietary RedTail platform features an engineered enveloped oncolytic virus designed for
systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune
clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $45.0K | — | — |
| R&D | $9.7M | $8.9M | $13.0M | $7.3M | — | — |
| SG&A | $10.5M | $12.9M | $16.0M | $15.9M | — | — |
| Total operating expenses | $20.2M | $21.8M | $29.0M | $23.2M | — | — |
| Operating income | -$20.2M | -$21.8M | -$29.0M | -$23.1M | — | — |
| Pre-tax income | -$20.0M | -$22.2M | -$29.2M | -$25.4M | — | — |
| Income tax | $15.0K | $14.0K | $16.0K | $11.0K | — | — |
| Net income | -$19.9M | -$22.1M | -$29.2M | -$25.4M | — | — |
| EPS, basic | -5.95 | -35.70 | -17.33 | 2.99 | — | — |
| EPS, diluted | -5.95 | -35.70 | -17.33 | 2.99 | — | — |
| Shares, diluted (wtd. avg.) | 4,302 | 667 | 1.7M | 8.5M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $5.8M | $9.8M | $2.2M | $590.0K | $2.2M | — |
| Receivables | — | — | — | $870 | $0 | — |
| Total current assets | $6.3M | $10.2M | $4.3M | $786.0K | $1.5M | — |
| Property, plant and equipment | $781.0K | $869.0K | $1.3M | $887.0K | — | — |
| Total assets | $8.9M | $14.2M | $10.0M | $2.6M | $231.8M | — |
| Accounts payable | — | — | — | $51.1K | $63.8K | — |
| Short-term debt | $90.0K | $3.2M | $807.0K | $5.4M | — | — |
| Total current liabilities | $3.9M | $9.5M | $10.2M | $43.0M | $411.0K | — |
| Long-term debt | $600.0K | $600.0K | $2.1M | — | — | — |
| Total liabilities | $5.1M | $12.2M | $18.3M | $43.4M | $16.5M | — |
| Retained earnings | -$141.6M | -$121.7M | -$99.6M | -$70.4M | -$14.7M | — |
| Total equity | $3.8M | $1.5M | -$8.2M | -$50.4M | -$31.6M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$21.3M | -$19.7M | -$27.0M | -$13.2M | — | — |
| Depreciation and amortisation | — | $402.0K | $392.0K | $260.0K | — | — |
| Stock-based compensation | $2.1M | $3.0M | $4.8M | $4.5M | — | — |
| Investing cash flow | -$170.0K | -$16.0K | -$478.0K | -$494.0K | — | — |
| Financing cash flow | $17.5M | $27.4M | $29.0M | $12.1M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013242.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $45.0K | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Net income | — | — | -$25.4M | -$29.2M | -$22.1M | -$19.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |